M. Dahlbom

University of California, Los Angeles

Papers

1

Total Citations

4

H-Index

1

About

M. Dahlbom is a prominent researcher in the field of urologic oncology, with a specialized focus on prostate cancer recurrence and advanced surgical interventions. Their major contributions center on the clinical application of prostate-specific membrane antigen (PSMA) radioguided salvage lymphadenectomy, a cutting-edge technique for managing biochemical recurrence after initial prostate cancer treatment. Dahlbom’s work, including a prospective exploratory trial published in 2024, has demonstrated the feasibility and short-term efficacy of PSMA-guided salvage pelvic lymph node dissection, offering new hope for patients with limited nodal relapse. This study, already garnering 4 citations shortly after publication, highlights Dahlbom’s role in translating molecular imaging into targeted surgical practice. By evaluating clinical responses and refining patient selection, Dahlbom has advanced personalized treatment strategies in a challenging clinical scenario. Their research bridges the gap between diagnostic precision and therapeutic action, making a tangible impact on the management of recurrent prostate cancer. Dahlbom’s contributions are particularly notable for their direct clinical relevance, providing a framework for future trials and potentially improving outcomes for patients facing disease progression.

Research Focus

Key Achievements

1
H-Index
1
Papers
4
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial
4 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: University of California, Los Angeles

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago